Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab

George P Kim, Axel GrotheyCollege of Medicine, Mayo ClinicAbstract: The human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, panitumumab, represents a significant advance in the treatment of colorectal cancer. The strategy to target this receptor is based on sound cancer biology d...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	George P Kim, Axel Grothey
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/57281556fa324096a7bb22e95eedc8df
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:57281556fa324096a7bb22e95eedc8df
record_format	dspace
spelling	oai:doaj.org-article:57281556fa324096a7bb22e95eedc8df2021-12-02T07:46:25ZTargeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab1177-54751177-5491https://doaj.org/article/57281556fa324096a7bb22e95eedc8df2008-06-01T00:00:00Zhttp://www.dovepress.com/targeting-colorectal-cancer-with-human-anti-egfr-monoclonocal-antibodi-a1728https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491George P Kim, Axel GrotheyCollege of Medicine, Mayo ClinicAbstract: The human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, panitumumab, represents a significant advance in the treatment of colorectal cancer. The strategy to target this receptor is based on sound cancer biology demonstrating its essential role in colorectal carcinogenesis. Panitumumab, unlike its predecessor, cetuximab, is fully human and thus reduces the incidence of hypersensitivity reactions. But, in several clinical trials, unexpected toxicities have become more apparent, raising concerns of how readily panitumumab can succeed cetuximab. This paper reviews the development of this agent and the pivotal clinical trials that help our understanding of its optimal use in colorectal cancer treatment.Keywords: colorectal cancer, chemotherapy, panitumumab, oxaliplatin, irinotecan, bevacizumab, cetuximab George P KimAxel GrotheyDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 2, Pp 223-228 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 George P Kim Axel Grothey Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
description	George P Kim, Axel GrotheyCollege of Medicine, Mayo ClinicAbstract: The human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, panitumumab, represents a significant advance in the treatment of colorectal cancer. The strategy to target this receptor is based on sound cancer biology demonstrating its essential role in colorectal carcinogenesis. Panitumumab, unlike its predecessor, cetuximab, is fully human and thus reduces the incidence of hypersensitivity reactions. But, in several clinical trials, unexpected toxicities have become more apparent, raising concerns of how readily panitumumab can succeed cetuximab. This paper reviews the development of this agent and the pivotal clinical trials that help our understanding of its optimal use in colorectal cancer treatment.Keywords: colorectal cancer, chemotherapy, panitumumab, oxaliplatin, irinotecan, bevacizumab, cetuximab
format	article
author	George P Kim Axel Grothey
author_facet	George P Kim Axel Grothey
author_sort	George P Kim
title	Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
title_short	Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
title_full	Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
title_fullStr	Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
title_full_unstemmed	Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
title_sort	targeting colorectal cancer with human anti-egfr monoclonocal antibodies: focus on panitumumab
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/57281556fa324096a7bb22e95eedc8df
work_keys_str_mv	AT georgepkim targetingcolorectalcancerwithhumanantiegfrmonoclonocalantibodiesfocusonpanitumumab AT axelgrothey targetingcolorectalcancerwithhumanantiegfrmonoclonocalantibodiesfocusonpanitumumab
_version_	1718399155013943296

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab

Ejemplares similares